This study is a Phase I, intravenous, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PZ-128 (pepducin inhibitor of PAR1) in subjects with vascular disease or who have 2 or more coronary artery disease (CAD) risk factors.

Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

Demonstration of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Antiplatelet Effect of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

Treatment Trials

Focus your search

Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

Description

Conditions